Yüklüyor......
Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
The treatment of patients with myelodysplastic syndromes (MDSs) has hinged primarily on supportive care (ie, blood transfusions, colony stimulating agents, iron chelation, etc.) and the US Food and Drug Administration-approved agents, including 5-azacytidine, deoxyazacytidine, and lenalidomide. For...
Kaydedildi:
| Yayımlandı: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
American Society of Hematology
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142467/ https://ncbi.nlm.nih.gov/pubmed/27913518 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|